In vitro bactericidal and in vivo therapeutic activities of a new rifamycin derivative, KRM-1648, against Mycobacterium tuberculosis.
The in vitro and in vivo activities of a new rifamycin derivative, KRM-1648, against Mycobacterium tuberculosis H37Rv were compared with those of rifampin. Bactericidal activity was evaluated by using a silicone-coated slide culture method. The MBC of KRM-1648 was 0.15 to 0.3 microgram/ml for 24 h o...
Na minha lista:
| Publicado no: | Antimicrob Agents Chemother |
|---|---|
| Principais autores: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society for Microbiology (ASM)
1996
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC163127/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/8834891/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.40.2.426 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|
